JP Morgan Reinstates Overweight on Mirum Pharmaceuticals, Announces $37 Price Target
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Jessica Fye has reinstated Mirum Pharmaceuticals (NASDAQ:MIRM) with an Overweight rating and set a price target of $37.

November 20, 2023 | 1:14 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JP Morgan analyst Jessica Fye reinstated Mirum Pharmaceuticals with an Overweight rating and a $37 price target, indicating a positive outlook for the stock.
The reinstatement of an Overweight rating by a major financial institution like JP Morgan, accompanied by a specific price target, typically signals confidence in the company's prospects and can lead to increased investor interest and a potential rise in the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100